Introduction: Obesity is a condition of abnormal or excessive fatness, and dyslipidemia is a condition with abnormal raised levels of any one or all lipids in the blood. Ayurveda compares signs and symptoms of obesity and dyslipidemia with the disease Sthaulya/Medoroga. Vyoshadi Guggulu and Haritaki Churna are the most commonly used medicines in the management of Sthaulya. However, the safety of these drugs was not evaluated until now through clinical trials.
INTRODUCTION
Obesity is a state in which weight exceeds a standard based on height. The risk of obesity appears to increase as the percent fat content in the body rises above an upper limit of normal. The definition of overweight and obesity is based on body mass index (BMI), which is measured as weight (in kilograms) divided by square of height (in meters). A healthy BMI range is 18.5 to 24.9 kg/m 2 . Overweight is defined as a BMI from 25 to 29.9 kg/m 2 , and obesity is defined as BMI ≥ 30 kg/m 2 . BMI value with combination of waist circumference can be used to evaluate health risk for individuals. 1 Obesity can lead to hazardous health consequences including type II diabetes, coronary artery disease, dyslipidemia, stroke, heart failure, hypertension, fatty liver disease, sleep apnea, osteoarthritis, and reproductive and gastrointestinal cancers. 2 Lipoprotein metabolism disorders, viz., overproduction and deficiency of lipoprotein, is known as dyslipidemia. These disorders may be manifested in the body due to the elevation of the serum total cholesterol, low-density lipoprotein cholesterol, and triglyceride concentrations, and a decrease in the concentration of
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high-density lipoprotein (HDL) cholesterol. 3 Dyslipidemia is a main risk factor in the pathophysiology of cardiovascular diseases and diabetes mellitus. 4 It is reported that the abnormality in cholesterol level causes 18% of the global cardiovascular diseases and 56% of the global ischemic heart diseases. It is also studied that for every 1% reduction in lipid levels, the risk of heart diseases reduces by 2.5%. 5 This study was undertaken by the National Foundation of India among the middle class (officers), lower class (clerks and peons) in a large office establishment and the poor class from a slum in New Delhi. Obesity of 1% for males and 4% for females was found in slums; the corresponding figures in the middle class were 32.3% and 50%. More females than males have been found to be overweight (BMI > 25) in all age groups, 44.5% females vs 19.6% males. Incidence of obesity was higher in people above 40 years of age. The prevalence of obesity (BMI > 30) was about 3% in males and about 14% in females above 40 years of age. 6 About 20 million Indians are obese and by 2025 the expected number shall be 68 million. 7 The different texts of Ayurveda have explained the disease Sthaulya/Medoroga in detail which is symptomatically similar with obesity and dyslipidemia. With the current "back to nature" thrust, many obese subjects also look for some help from the traditional systems like Ayurveda. 8 The societal factors that promote sedentary lifestyles and the consumption of high-fat, energy-dense diets are mainly responsible for global epidemic of obesity. 9 Apart from this, genes also play an important role in the determination of a person's susceptibility to weight gain. 10 Ayurveda classical texts also consider dietetic, behavioral pattern, and psychological factors as causes of Sthaulya. Ahara Atisampurna (excessive intake of food) plays the major role in the causation of obesity. The objective of the studies was to assess the safety of Vyoshadi Guggulu and Haritaki Churna in obese and dyslipidimic subjects.
Drug Profile
The composition of the drug is given in Table 1 .
OBJECTIVE
Critical analysis of clinical safety of classical Ayurvedic formulations, viz. Vyoshadi Guggulu and Haritaki Churna, in the management of obesity (Sthaulya) and dyslipidemia.
MATERIALS AND METHODS
The formulations fulfilling the physicochemical standards and quality parameters, and prepared as per standard operating procedures, were procured from good manufacturing practices-certified companies for the studies. These two different clinical studies were approved by institutional ethics committee of all the participating centers and done in accordance with WHO Good Clinical Practice Guidelines. Both clinical trials were registered under Clinical Trial Registration of India. Open-label, multicenter clinical trial was carried out in selected peripheral institutes of CCRAS. Follow-up was done every 2 weeks to record the onset of any adverse reaction during the intervention. The data obtained were analyzed to assess the safety of Vyoshadi Guggulu and Haritaki Churna through LFTs and KFTs.
Study I-Clinical Evaluation of Vyoshadi Guggulu and Haritaki Churna in the Management of Obesity (Sthaulya) (CTRI/2012/03/002527)
A total of 160 participants were enrolled in the trial from three peripheral institutes. Patients were screened in accordance with the inclusion and exclusion criteria and were recruited after obtaining the written informed consent. The patients were administered Vyoshadi Guggulu in a dose of 1.5 gm (3 tablets of 500 mg each) twice daily and Haritaki Churna in a dose of 3 gm twice daily for a period of 12 weeks (i.e., 84 days). Both the drugs were advised before food and with lukewarm water. After the end of treatment period of 12 weeks, patients were also followed without medications till 14 weeks to check any adverse reaction. Out of the total 160 patients enrolled in the study, 20 dropped out during the course of the study. Intention-to-treat analysis was done and the data of all those patients who have completed at least 14th day visit were imputed by last observation carried forward (LOCF) method. Patients who dropped out after baseline visit only were excluded from analysis. Hence, data of a total 160 patients were used for statistical analysis.
Study II-Clinical Evaluation of Vyoshadi Guggulu and Haritaki Churna in the Management of Dyslipidemia-(CTRI/2012/03/002528)
A total of 146 individuals were enrolled in the study conducted at 3 peripheral research institutes. Patients were screened in accordance with the inclusion and exclusion criteria and were recruited after obtaining the written informed consent. Vyoshadi Guggulu was administered orally in a dose of 1 gm (2 tablets of 500 mg each) thrice daily after food with lukewarm water and Haritaki Churna in a dose of 3 gm twice daily for 12 weeks. The trial drugs were administered for 12 weeks with a follow-up at the end of 14 weeks without any interventions. Total 146 subjects were enrolled in the study. Fifty dropped out during the course of the study. Intention-to-treat analysis was done, and the data of all those patients who have completed at least 14th day visit were imputed by LOCF method. Patients who dropped out after baseline visit only were excluded from analysis. Hence, data of a total 146 patients were used for statistical analysis.
Statistical Analysis
Laboratory parameters at the beginning and at the end of the trial period were compared using paired t-test. A p-value of <0.05 was considered significant. All statistical analysis was performed using Statistical Package for the Social Sciences (SPSS), version 15.0.
OBSERVATIONS
Effect of Vyoshadi Guggulu and Haritaki Churna on Obesity
Total 160 subjects completed the trial. The majority of the subjects were females (80.6%). About 91.3% knew how to read and write, 80% patients belonged to above poverty line, and 84.4% were non-vegetarian. It was also observed that maximum number of subjects (56.3%) were of Pitta-Kaphaja Prakriti. Table 2 shows the basic information and demographic profile of the subjects. Combination of Vyoshadi Guggulu and Haritaki Churna was found effective in the management of obesity which could be ascertained by its effect on the outcome para meters, viz., BMI, waist circumference, hip circumference, waist-hip ratio, lipid profile, and all the eight domains of Short form 36 (SF-36
14 Health Survey Questionnaire; p < 0.001). The effect of this treatment on LFTs and renal function tests was assessed at baseline and at day 84 of the trial. The values were within stipulated range during the entire trial period (Table 3 , Graphs 1 to 3). Further, no adverse drug effect or adverse events were reported during the treatment period.
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Effect of Vyoshadi Guggulu and Haritaki Churna on Dyslipidemia
Total 146 subjects completed the trial. The majority of the subjects were females (64.4%), and 87.7% knew how to read and write. About 82.9% belonged to above poverty line, and 71.9% were non-vegetarian. It was also observed that maximum number of subjects (71.9%) were of PittaKaphaja Prakriti. Table 2 shows the basic information and demographic profile of the subjects. Combination of Vyoshadi Guggulu and Haritaki Churna was found effective in the management of dyslipidemia which could be ascertained by its effect on the outcome parameters. There was a significant reduction (p = 0.003) in the mean serum cholesterol level. Moreover, mean HDL and mean scores of all the eight domains of SF-36 Health Survey Questionnaire were also statistically significant (p-value < 0.001) as compared before and after treatment. The effect of this treatment on LFTs and renal function tests was assessed at baseline and at day 84 of the trial. The values were within range during the entire trial period (Table 3 , Graphs 1 to 3). Further, no adverse drug effect or adverse events were reported during the treatment period.
The data, regarding demographic profile and safety, obtained from both studies are given in Tables 2 and 3 and Graphs 1 to 3.
Open-label multicenter clinical trials were done in selected peripheral institutes of CCRAS to evaluate the safety and efficacy of Vyoshadi Guggulu and Haritaki Churna in the subjects of obesity and dyslipidemia, and the details are briefed in Table 4 . Follow-up was done every 2 weeks to record the onset of any adverse reaction during the intervention and also after completing the study. The data, regarding demographic profile, efficacy, and safety, obtained from the both studies are given in Tables 2 and 3 and Graphs 1 to 3.
DISCUSSION AND CONCLUSION
Kapha and Medadhatu play vital role in the pathogenesis of the Sthaulya. Kaphavardhaka Ahara (Kapha elevating food), absence of physical activities, and Diwaswapna (day sleep) leads to incomplete processing of Anna Rasa (consumed food), which is converted into Ama Dosha. 15 It leads to Medodhtavagni Mandyata. In the case of Sthaulya, the Medadhatwagnimandya leads to Vriddhi of Medadhatu and associated dyslipidemia. Charaka described Sthaulya is a Santarpan janya vyadhi and he recommended "Guru cha Aptarpana" Chikitsa. Kapha Dosha and Meda Dhatu are the main causative factors and mutually dependent on each other. So, any causative factor which increases Kapha dosha will result in the increase of Medas resulting to dyslipidemia. Apart from these two, Vata and Agni also plays an important role in pathogenesis of these diseases. 11 Hence the treatment must be focused on alle- Modern studies on the ingredients of Vyoshadi Guggulu and Haritaki Churna also have established their hypolipidemic, hypocholesterolemic, and anti-dyslipidemic actions. Oleo gum resin of Guggulu has been found to be effective in reducing serum cholesterol, estrogen-induced hyperlipidemia, and hypercholesterolemia. 18 Guggulsterone has reported to reduce serum cholesterol, triglyceride, 19 and having cardioprotective action. 20 The hypolipidemic action of Haritaki has been explained through inhibition of cholesterol biosynthesis, increased fecal bile acid excretion, and enhanced plasma cholesterol acyl transferase activity. Triphala has also been found to have potent hypolipidemic effect and have shown to be potent in reducing hypercholesterolemia and atherosclerosis. 21, 22 Piperine significantly possesses a lipid-lowering effect and antiobesity activity without any change in appetite. 23 Piper nigrum L. extracts have shown results in reducing the 24 Ginger (Zingiber officinale Roscoe, Zingiberaceae) has been reported to ameliorate hyperlipidemia, hyperglycemia, oxidative stress, and inflammation. 25 It has potential in managing obesity, accompanying with an intervention-genotype interaction effect. 26 The inhibition of intestinal absorption of dietary fat was reported by the active compounds of Z. officinale.
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Both drugs have Kaphamedohara (Kapha and Meda alleviating) action according to Ayurveda, and also there are evidences of these drugs having activity on lipid profile. Hence, administration of Vyoshadi Guggulu and Haritaki Churna for 12 weeks is very commonly used to cure conditions like hypercholesterolemia and obesity.
The purpose of these studies was to assess the safety profile of these formulations by comparing LFTs and KFTs before and after the treatment. Both formulations were given in different disease conditions, obesity and dyslipidemia, in different clinical studies executed in peripheral institutes of CCRAS. Although there was slight change in LFT and KFT before and after the Ayurvedic interventions, but the change was within normal limits. None of the patients complained of any adverse reaction or side-effects during these studies.
It can be concluded from these studies that these two Ayurvedic formulations are safe as far as liver and renal functions are concerned, and these were well tolerated by the participating subjects.
These studies ascertain that the Ayurvedic formulations are safer for short term and long term consumption as far as renal functions are concerned. The data collected from these studies provide a positive conclusion that the Ayurvedic medicines are safe. The Ayurvedic medicines are safe if each ingredient is procured after fulfilling standard guidelines and prepared under proper guidance.
Further exploration with larger samples can be taken to establish the safety concern.
